Picture of UK Houses of Parliament

Leading national thinking on politics, government & public policy through Open Access research

Strathprints makes available scholarly Open Access content by researchers in the School of Government & Public Policy, based within the Faculty of Humanities & Social Sciences.

Research here is 1st in Scotland for research intensity and spans a wide range of domains. The Department of Politics demonstrates expertise in understanding parties, elections and public opinion, with additional emphases on political economy, institutions and international relations. This international angle is reflected in the European Policies Research Centre (EPRC) which conducts comparative research on public policy. Meanwhile, the Centre for Energy Policy provides independent expertise on energy, working across multidisciplinary groups to shape policy for a low carbon economy.

Explore the Open Access research of the School of Government & Public Policy. Or explore all of Strathclyde's Open Access research...

Schizophrenia in the 21st century : new insights and translation into improved therapies

Pratt, Judith (2015) Schizophrenia in the 21st century : new insights and translation into improved therapies. Journal of psychopharmacology (Oxford, England), 29 (2). pp. 83-84. ISSN 1461-7285

[img]
Preview
Text (Pratt-JOP-2015-Schizophrenia-in-the-21st-century-new-insights-and-translation)
Pratt_JOP_2015_Schizophrenia_in_the_21st_century_new_insights_and_translation.pdf
Accepted Author Manuscript

Download (288kB)| Preview

    Abstract

    Over 100 years have elapsed since schizophrenia was first described and over 50 years since chlorpromazine was utilised to alleviate hallucinations and delusions characteristic of the disorder. With the introduction of a swathe of antipsychotic drugs from the 1970s to date, there have been waves of optimism for improvements in the clinical efficacy of these drugs. Unfortunately, these treatments have not fulfilled expectations. As with chlorpromazine, current medications provide relief for the positive symptoms through dopamine D2 receptor antagonism, but have limited impact on the negative symptoms and cognitive deficits. Moreover, potential drug-induced side effects such as motor dysfunction and weight gain are highly undesirable. Lack of understanding of the causes of schizophrenia together with the continued use of dopamine-based preclinical models in drug discovery, with read-outs of limited translational relevance, are arguably key factors in the lack of major breakthroughs for improved treatments.